Wednesday, June 21, 2017 5:07:49 AM
Love this bit: "With FDA approval, the CTL019 CAR-T cell therapy would no longer be constrained to clinical trials—effectively making this life-saving cancer immunotherapy treatment accessible to many more children around the world! "
http://emilywhiteheadfoundation.org/tom-whitehead-to-speak-at-fda-approval-hearing-car-t-cell-therapy-ctl019/
British company Oxford BioMedica is the sole manufacturer of the lentiviral vector expressing CTL019 for Novartis. The commercial launch of CTL019 is anticipated by Novartis later this year and Oxford BioMedica will receive undisclosed royalties on potential future sales of Novartis CAR-T products.
Oxford Biomedica are developing further immunotherapies with Novartis for many other cancers.
http://www.oxfordbiomedica.co.uk/investor-contacts/
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM